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Roux-en-Y gastric bypass surgery (RYGB) is effective for weight loss, but 
is commonly associated with iron deficiency and its clinical manifestation, anemia. 
Diagnosing iron deficiency is complex because iron status depends on other 
nutrients; additionally, anemia following surgery is not specifically due to 
deficiency in iron, as it can be due to deficiencies in other nutrients including zinc, 
copper, vitamin B6, folate, and vitamin B12. In patients who have undergone 
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients 
involved in iron homeostasis, 2) determine the contribution of dietary intake to 
iron deficiency, and 3) describe associations between anemia and nutritional 
status of iron and other nutrients. Systemic measures of hemoglobin, ferritin, 
serum transferrin receptor (sTfR), total iron binding capacity (TIBC), copper (Cu), 
vitamins B6 and B12, folate, zinc (Zn), and C-reactive protein (CRP) were 
determined using reference methods. Iron deficiency equaled having ≥ 2 
abnormalities in: ferritin, sTfR, sTfR:ferritin, or TIBC. Ferritin, a measure of iron 
stores, was defined as normal (ferritin ≥ 20 mcg/L) or low (ferritin < 20 mcg/L). 
Statistics included prevalence, mean ± standard error of the mean (s.e.m.) for 





(indicated with an asterisk [*]), frequency tables, t-tests (independent, by group), 
correlations, and general linear models (significant if p < 0.05). Subjects (N=70) 
were 91% female, age 49 ± 1 years, *4 ± 2 years post surgery, and 79% 
Caucasian. Fifty-six percent of the total population and 96% of the subpopulation 
with anemia (N=26) presented with deficiencies related to iron nutriture, including 
deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12. The most 
prevalent nutrient deficiencies in the total population and the subpopulation with 
anemia were iron and zinc; prevalence of iron and zinc deficiency in the total 
population was 24.3% and 20.0%, respectively, and prevalence of iron and zinc 
deficiency in the subpopulation with anemia was 46.2% and 23.1%, respectively. 
Participants in the total population and the subpopulation with anemia were also 
deficient in copper, vitamin B6, vitamin B12, and folate (11.5% and 26.9%, 
respectively).  In the total population, iron and zinc deficiency occurred in 
isolation and also in combination with other nutrient deficiencies; all other nutrient 
deficiencies occurred in combination. In the subpopulation with anemia, only iron 
deficiency occurred in isolation. The dietary intake of the study population 
exceeded the RDAs for all nutrients assessed.  In addition, patients with low 
ferritin concentrations consumed lower total energy (p= 0.009), fat (p= 0.026), 
protein (p=0.013), and animal protein (p=0.023), compared to patients with 
normal ferritin concentrations. Dietary intake of heme iron was correlated with 
years post-RYGB surgery (r=0.67, p<0.05). In conclusion, in a community-based 
surveillance of RYGB patients we found that, more often than not, RYGB patients 





deficiencies in iron, copper, zinc, vitamin B6, folate, and vitamin B12. It was more 
likely for multiple deficiencies to occur simultaneously than for deficiencies to 
occur alone. In addition, there was a high prevalence of anemia, a clinical 
manifestation of deficiencies in these nutrients. Implications of these findings are 
that clinicians who evaluate post-RYGB patients, especially patients who present 
with known symptoms or manifestations of iron deficiency, should also screen 
patients for deficiencies in copper, zinc, vitamin B6, folate, and vitamin B12, as 
these deficiencies are also prevalent following surgery, may occur 
simultaneously with iron deficiency, and are also implicated in anemia. Based on 
our findings that RYGB patients who have more favorable iron stores consume 
more energy, fat, and protein than patients with low iron stores, increasing 
protein intake following surgery may improve iron status; although, increasing 
consumption of fat may have detrimental effects on weight regain in the RYGB 
population. Findings of this study may be used to enhance prophylactic 







CHAPTER 1. INTRODUCTION 
1.1 Obesity and its Health Consequences 
Obesity is a significant health problem resulting in many comorbidities 
including diabetes, cardiovascular disease and cancer.1 Rates of moderate and 
severe obesity are continuing to rise in the United States.2 Although obesity is 
generally thought of as a condition of overnutrition, overweight and obesity are 
also known risk factors for deficiencies in various micronutrients, including 
vitamins A, E, B1 and B12, folate, selenium, chromium, zinc, and iron.
3,4 In 
particular, a high prevalence of iron deficiency is documented in the severely 
obese population (28%-35%).5-7 Bariatric weight loss surgery is growing in 
popularity as an effective, long-term treatment for moderate and severe obesity, 
but is also associated with iron deficiency (postoperative prevalence: 15-54%8-12). 
This chapter discusses iron deficiency, factors that contribute to iron homeostasis, 
the clinical manifestation of anemia, mechanisms for iron deficiency in obesity, 






1.2 Iron Deficiency and Homeostasis 
1.2.1 Iron Deficiency 
Iron deficiency is the most common and widespread nutritional disorder in 
the world, and the only nutrient deficiency that is significantly prevalent in 
industrialized nations.13,14 It is associated with increased infant mortality and 
perinatal risks for mothers and neonates, it adversely affects cognitive 
performance, behavior, and physical growth of infants and adolescents, as well 
as immune status, morbidity from infections, physical capacity, and work 
performance in all age groups.13 Therefore, patients who develop iron deficiency 
have a decreased quality of life.  Severe iron deficiency is associated with low 




The causes of iron deficiency are multifactorial. Iron deficiency may be 
caused by blood loss due to disease, infection, hemorrhage in childbirth, 
menstruation, or trauma. Iron deficiency may also be nutrient-related as a 
consequence of poor diet quality, such as low intake of bioavailable iron, deficits 
in specific nutrients, e.g. copper, vitamin B6 and zinc which are required for iron 
absorption and heme synthesis, or high concentrations of nutrients that compete 





referring to the physiological state of the host, such as inflammation and/or 
mechanical alterations due to gastrointestinal surgery.4 
The multifactorial etiology of iron deficiency includes true and functional 
iron deficiency.  The former is characterized by reduced iron stores, while the 
latter describes a compromised supply of iron to tissues and/or mobilization of 
iron between tissues. Functional iron deficiency can be affected by conditions 
such as obesity-induced inflammation and thus is highly dependent on the 
systemic state of the individual. 
 
1.2.2 Iron Homeostasis 
Because of iron’s central role in oxygen and energy metabolism, iron 
absorption, utilization and storage are tightly regulated to maintain homeostasis. 
Unlike other essential elements, iron is highly conserved. Total iron body content 
is estimated to be 3800 mg in men and 2300 mg in women; relatively small 
amounts of iron are lost in feces (~0.6 mg/day), urine (<0.1 mg/day) and sweat 
(<0.3 mg/day).15 Because there are no other excretion routes for iron and iron is 
mainly lost through blood, fecal iron content can be used to indirectly measure 
iron absorption. Approximately 20 to 25 mg of iron is recycled daily with the 
erythrophagocytosis of senescent red blood cells in the spleen, and iron that is 
released from heme is captured and reutilized to produce new erythrocytes in 
bone marrow.15 The body also contains a large storage pool for iron (in its 






1.2.2.1 Intestinal Iron Absorption 
1.2.2.1.1 Heme and Non-Heme Iron 
There are two bioavailable forms of iron that are obtained from the diet:  
heme and non-heme iron. The more bioavailable heme iron is found in meat, fish 
and poultry; about 40% of the iron is bound into heme while the other 60% is 
non-heme iron.16 The form of iron primarily found in grains, vegetables and 
legumes is non-heme iron. For meat-eating individuals, heme iron makes up 
about two-thirds of the iron that is absorbed. Heme iron is soluble at the pH of the 
duodenum where most iron absorption occurs, and is not affected by the dietary 
constituents that impair non-heme iron absorption such as phytates, polyphenols, 
oxalates, calcium and other divalent cation minerals.17 Co-consumption with 
vitamin C - rich foods,18-21 and meat, fish and poultry22-25 enhances non-heme 
iron absorption.17,26 There is a high incidence of iron deficiency anemia in 
countries where meat is less available because of the predominance of non-
heme iron-containing foods in the diet.27  
 
1.2.2.1.2 Mechanism for Intestinal Iron Absorption 
Iron homeostasis is controlled at the level of intestinal absorption. Iron 
absorption is an important determinant of iron homeostasis and is highly 
regulated.  Iron absorption increases when iron stores are low and decreases 





understood than heme iron. The abbreviated mechanism of iron passage across 
the enterocyte is shown in figure 1.1:28  
 
 
Figure 1.1 Iron Passage Across the Enterocyte. Ferric iron is reduced by the 
brush border ferric reductase, Dcytb, before being transported into the cell via 
Dmt1. Iron is either stored as ferritin or exported into the circulation across the 
basolateral membrane via Fpn1. The iron oxidase, Hp, converts ferrous iron to 
ferric iron for efficient export. Iron circulates bound to Tf. Liver-derived Hepcidin 
reflects systemic iron demands, and removes Fpn1 from the plasma membrane 
in order to prevent iron export. 
 
First, the membrane-bound ferroxidase duodenal cytochrome b (Dcytb) 
reduces ferric iron (Fe3+) to ferrous iron (Fe2+). Then, divalent metal transporter-1 
(Dmt1) transfers molecular Fe2+ from the luminal side into the enterocyte. Iron 
entering the enterocyte is either incorporated into ferritin, the storage form of iron, 
or subjected to basolateral export by transmembrane protein ferroportin 1 (Fpn1). 
Ferrous iron then undergoes oxidation by the membrane-bound copper-
containing ferroxidase hephaestin (Hp) before being incorporated into transferrin, 





addition to intestinal absorptive cells, ferroportin is on the surface of hepatocytes, 
macrophages and placental cells, all of which release iron into the plasma.30  
Hepcidin is a liver-derived peptide implicated in the control of iron homeostasis. 
Hepcidin inhibits iron absorption by binding to ferroportin, targeting its 
degradation, and ultimately blocking iron efflux.28,29 Therefore, hepcidin blocks 
intestinal iron absorption and release in various cell types. Genes associated with 
hereditary hemochromatosis (a genetic disease causing the body to absorb too 
much iron), HFE and TFR2, have been found to regulate hepcidin levels through 
an iron-sensing mechanism.15,31-33 
 
1.2.2.2 Heme Synthesis 
Most body iron is found as heme iron; heme is the essential constituent for 
oxygen transport and storage, electron transport in aerobic respiration and signal 
transduction. Therefore, the synthesis of heme iron is vital. Heme synthesis 
occurs primarily in bone marrow, where red blood cells are synthesized, and in 
the liver to carry out its function in the cytochrome system. Of importance is that 
heme synthesis relies on vitamin B6 and zinc, thus deficiencies in these nutrients 
negatively impact iron homeostasis. 
 
1.2.2.3 Iron Toxicity 
Chronic iron toxicity can be associated with high dietary iron intake, 





with increased iron absorption.34 However, there are mechanisms in place to 
prevent toxic accumulation of iron, including the upregulation of hepcidin to 
reduce iron absorption, induction of ferritin to limit the availability of iron and the 
induction of antioxidant enzymes for protection against oxidant damage.35 
Therefore, the risk of iron toxicity is low. 
 
1.2.3 Assessment of Iron Status  
There are several methods of assessing iron status and diagnosing iron 
deficiency, and the precise cutoff values often differ by laboratory. The most 
specific test for depletion of iron storage is low serum ferritin. However, ferritin is 
an acute-phase protein and is thus increased in a state of chronic or acute 
inflammation.36,37 Therefore, this method is not always reliable since high ferritin 
may occur during conditions of low iron status. Serum iron, the amount of iron in 
the blood, is not representative of the amount of iron stored in the body, and 
therefore this test is rarely informative on its own.38 Transferrin is a protein that 
transports iron in blood via reversible binding. Total iron-binding capacity (TIBC) 
measures how much of transferrin in circulation is iron-free.38 Thus, elevated 
TIBC indicates poor iron status. Transferrin saturation index is the ratio of serum 
iron to TIBC and represents how much serum iron is bound to transferrin. Low 
transferrin saturation indicates iron deficiency. The soluble form of transferrin 
receptor present in serum (sTfR) is proportional to the amount of surface 
receptors;15 sTfR expression is translationally regulated and is increased when 






The widely known clinical manifestation of iron deficiency is anemia. 
Anemia is generally characterized by low hemoglobin concentrations (<12 g/dL 
for menstruating females and <13 g/dL for men and post-menopausal females). 
The World Health Organization (WHO) estimates that 39% of children less than 5 
years of age, 48% of 5-14 year-old children, and 42% of women in developing 
countries suffer from anemia, but iron deficiency is present in only half of these 
individuals.13 Anemia is also a consequence of deficiencies in other nutrients 
including copper, vitamins B6 and B12, folate, and zinc, which adds to the 
complexity of effectively diagnosing and treating iron deficiency. Anemia resulting 
from iron, copper and vitamin B6 deficiency is characterized as microcytic, while 
anemia due to deficiency in vitamin B12 and folate are characterized as 
megaloblastic. 
 
1.3.1 Microcytic Anemia: Iron, Copper and Vitamin B6 Deficiency 
1.3.1.1 Iron Deficiency Anemia (IDA) 
Severe iron deficiency is accompanied by microcytic, hypochromic anemia 
and is termed IDA.36,37 IDA is characterized by the aforementioned measures of 
iron depletion, as well as low mean corpuscular hemoglobin (MCH) and mean 






1.3.1.1.1 IDA Secondary to Copper Deficiency 
IDA may also occur secondary to copper deficiency. Hephaestin is a 
copper-containing ferroxidase that oxidizes ferrous iron to ferric iron, enabling 
iron to bind transferrin and enter circulation.39 Therefore, copper deficiency may 
also lead to functional iron deficiency and IDA.39 
 
1.3.1.2 Vitamin B6 and Zinc Deficiency 
Vitamin B6 and zinc are required for heme synthesis, and therefore 
deficiencies in these nutrients may result in anemia. Similar to iron deficiency 
anemia, vitamin B6 (pyridoxine) deficiency can manifest as microcytic, 
hypochromic anemia (low MCH and low MCV), but with normal or high serum 
concentrations of iron and ferritin.40 This type of anemia is generally named 
sideroblastic anemia,41 referring to ringed sideroblasts in the bone marrow,42 and 
is thought to be caused by insufficient hematopoiesis due to faulty heme 
synthesis.43 Pyridoxine-responsive anemia44 belongs to this group, as pyridoxine 
acts as a coenzyme in the process of heme synthesis.40 Since zinc is also 
required for heme synthesis, zinc deficiency may also manifest as microcytic, 
hypochromic anemia; however, there is a lack of evidence to support this in the 
literature. Therefore, in addition to iron and copper, deficiency in vitamin B6 and 







1.3.2 Megaloblastic Anemia: Vitamin B12 and Folate Deficiency 
Vitamin B12 and folate are important for the normal maturation of all cells, 
as they are needed for cell differentiation.45 Vitamin B12 and folic acid deficiency 
are characterized by megaloblastic anemia, which affects the development and 
morphology of blood cells. The anemia of folic acid deficiency has morphologic 
features indistinguishable from those of vitamin B12 deficiency, but it develops 
much more rapidly. 15,46-48 The cellular hallmarks are macrocytosis, which is 
easily detected by elevated erythroid MCV but not specific to megaloblastic 
anemia, and abnormal nuclear maturation that is more specific than 
macrocytosis.15,45 However, normocytic anemia (normal MCV) may be attributed 
to vitamin B12 and folate deficiency anemia in persons with coexisting 
microcytosis, possibly caused by iron deficiency anemia, which can blunt or 
eliminate the expected macrocytosis.49,50 Therefore, vitamin B12 and folate can 
lead to anemia; however, this type of anemia is characterized by macrocytosis, 
and thus may be distinguishable from microcytic anemia caused by iron, copper, 
vitamin B6 and zinc deficiency. 
 
1.3.3 Anemia of Chronic Disease (ACD) 
Anemia of Chronic Disease (or Anemia of Inflammation) may accompany 
chronic illness or inflammation, and is a protective mechanism that the body uses 
to limit the amount of iron that is available to harmful pathogens.51 When this 
defense system is activated, less iron is absorbed and excess iron is collected by 






in hemoglobin concentrations.51 There are three known mechanisms for ACD, 
which are all related to abnormal cytokine levels: 1) Dmt1 is upregulated and 
Fpn1 is downregulated by lipopolysaccharides, interferon-γ, and tumor necrosis 
factor-α (TNF-α), causing an increase in iron uptake by reticuloendothelial cells; 
2) Hepcidin is upregulated by lipopolysaccharides, interleukin 6 (IL-6), and 
possible interleukin-1 (IL-1), causing a reduction in iron absorption; 3) Erythroid 
progenitor expansion is inhibited by interferon-γ, IL-1, TNF-α, and interferon-β, 
causing disruption of red blood cell production.52  Patients with chronic or 
inflammatory disease are identified with high serum C reactive protein (CRP), low 
hemoglobin concentrations and low transferrin saturation.15,51 Because patients 
who have IDA may also have co-existing inflammation, it is difficult to 
differentiate between ACD and IDA. Since serum ferritin concentrations may be 
increased in patients who are inflamed with IDA, it may not be an accurate 
measure. To differentiate between the diagnoses of ACD with and without iron 
deficiency, TIBC and sTfR are useful. TIBC is low in ACD, unlike IDA, because 
there is ample iron but it is not readily available.51 Additionally, a derived value for 
the ratio of sTfR to log ferritin greater than 2 defines ACD with iron deficiency, 
whereas a ratio of sTfR to log ferritin less than 1 is typical in ACD without iron 
deficiency.53 Therefore, anemia may also be associated with conditions that are 







1.4 Iron Deficiency in Obesity 
Although iron deficiency is generally associated with under-nutrition, 
overweight individuals are also at a higher risk of iron deficiency than normal-
weight individuals. Several studies have shown an inverse relationship between 
an individual’s BMI and iron status.54-56 
 
1.4.1 Mechanisms 
Potential mechanisms for impaired iron status in the obese state include 
decreased dietary intake of iron and increased intake of dietary fat, impaired 
intestinal uptake and release of iron, and reduced iron bioavailability due to 
inflammation. Through these mechanisms, obesity can influence both true and 
functional iron deficiency. To add to the complexity, it is difficult to diagnose iron 
deficiency in the setting of obesity due to co-existing inflammation, which 
increases the release of acute-phase reactants such as ferritin and thus iron 
status may appear artificially high, even in a state of true iron deficiency.57  
 
1.4.1.1 Changes in Dietary Intake 
1.4.1.1.1 Dietary Iron Intake 
Low dietary intake of iron and high intake of other nutrients in obesity may 
contribute to iron deficiency. In a cross-sectional study of 512 adolescents, both 
overweight boys and girls had lower iron intakes than their non-overweight 
counterparts.58 However, other studies have not confirmed this finding. For 






deficiency was significantly more prevalent, mean serum iron was lower, and 
transferrin saturation was lower among obese compared with non-obese subjects, 
despite no differences in dietary iron intake between these groups. 59 In a cross-
sectional survey, the risk of iron deficiency in obese Mexican women and 
children was 2-4 times that of normal-weight individuals even though dietary iron 
intakes were similar.60 Therefore, it is not conclusive that low iron intake is the 
reason for poor iron status in obesity.  
 
1.4.1.1.2 Dietary Fat Intake 
Another study investigated the effect of high-fat-diet-induced obesity on 
iron metabolism in an animal model of diet-induced obesity. C57BL/6 mice were 
placed on a high fat content diet (HFD) or a standard diet (SD) with high 
carbohydrate content for eight weeks, and then further randomized to receive or 
not receive iron supplementation for an additional two weeks.29 Mice receiving 
the HFD had significantly higher body weight when compared with SD-fed 
C57BL/6 mice (P< 0.001). HFD feeding decreased serum and hepatic iron levels, 
and response to iron supplementation.29 Duodenal absorption of 59ferric citrate 
was significantly decreased in HFD-fed mice compared to SD-fed mice 60 and 
90 minutes after gavage (P<0.05).29 The authors further investigated the 
underlying mechanisms of reduced iron absorption in the HFD group by 
measuring the mRNA expression of duodenal oxidoreductases, and found that 






with or without iron supplementation.29 This data suggests that interaction 
between dietary iron and excess fat in the intestinal lumen may reduce iron 
absorption by reducing iron uptake and extrusion by oxidoreductases Dcytb and 
hephaestin, respectively.  
A human pilot study suggested that the type of dietary fat may also affect 
iron absorption. Three male cyclists consumed isoenergetic, isonitrogenous diets 
for 28-day periods in a randomized, crossover design in which dietary 
carbohydrate, polyunsaturated (PUFA), or saturated fat contributed to roughly 50% 
of daily energy intake.61 Fecal iron increased and iron balance (intake – loss) 
decreased with the diet high in polyunsaturated fat. Similarly, fecal iron increased 
and iron balance decreased with an increase in lineolate intake.61 Since fecal iron 
is an indirect measure of iron absorption, this study suggests that iron absorption 
decreases with a diet high in PUFA, particularly linoleic acid.61 However, a diet 
high in saturated fat did not have the same effect. Therefore, larger clinical 
studies are needed to determine a relationship between consumption of specific 
dietary fats and iron absorption. 
 
1.4.1.2 Obesity-induced Inflammation 
Obesity induces low-grade, chronic, systemic inflammation that may 
contribute to reduced iron absorption and bioavailability, resulting in true and 
functional iron deficiency. This is illustrated by a clinical study of 92 






correlated with CRP (p<0.001) and BMI (P<0.05) independent of serum ferritin 
levels, and CRP was significantly positively correlated with BMI.55 This data 
suggests that adiposity-induced inflammation is associated with lower fractional 
iron absorption in humans. The authors hypothesized that inflammation-induced 
hepcidin was likely causing a decrease in dietary iron absorption by reducing 
Fpn1 expression, known as the “Hepcidin Mechanism.” 
 
1.4.1.2.1 Hepcidin Mechanism 
Several authors speculate that increased circulating hepcidin in obesity 
may be a contributing factor leading to the reduced iron status observed in the 
obese population.30,55 In support of this claim, both cell culture and human 
studies suggest that hepcidin levels are increased in obesity. The inflammatory 
adipokine, leptin, which is secreted by adipose tissue and circulates at levels 
proportional to body fat, promoted hepcidin expression in HuH7 human 
hepatoma cells in a dose-dependent manner.62 In a human study of 105 
candidates for bariatric surgery and 60 control subjects who were stratified 
according to BMI category, moderate and severe obesity (BMI > 35 kg/m2) were 
significantly associated with higher serum hepcidin concentration.63 These data 
support the notion of increased hepcidin levels in obesity. Furthermore, in a study 
of 60 obese children and 50 control subjects, a direct correlation between 
hepcidin and obesity degree (P=0.0015) were observed, as well as inverse 






absorption (P=0.003).64 This serves as evidence for the link between obesity, 
hepcidin, and impairment of iron status.  
Another study explored the tissue-specific role of hepcidin in iron 
regulation. This study included three groups of obese patients (obese, obese with 
diabetes, and obese with nonalcoholic steatohepatitis [NASH]), control adipose 
tissue from lean females, and control liver samples which were histologically 
normal and non-inflamed from males and females. These patients were 
investigated to determine the possible role of hepcidin in severe obesity.65 Low 
transferrin saturation was observed in 68% of the patients and 24% of these 
patients presented with anemia.65 Hepcidin mRNA and protein levels in 
subcutaneous adipose tissue (SAT) were significantly enhanced in all obese 
conditions compared to control adipose tissue samples, and SAT hepcidin mRNA 
expression was correlated with the BMI of the patients; there was no effect of 
diabetes or NASH on hepcidin expression levels in liver or adipose tissue. Also, 
the hepcidin mRNA concentration in adipose tissue was related to the expression 
of inflammatory markers CRP and IL-6. However, hepcidin expression in adipose 
tissue was similar in iron-depleted and iron non-depleted obese groups, 
suggesting that adipose-derived hepcidin may play a minimal role in iron 
mobilization in obesity.65 Interestingly, liver biopsy showed that hepatic hepcidin 
mRNA expression levels in obese individuals were not significantly different from 
those of control liver samples. Still, there was a negative correlation found 
between liver, but not adipose tissue, hepcidin expression and serum transferrin 






specific.65 Thus, further studies are needed to determine the role of adipose 
versus hepatic production of hepcidin and adverse effects on iron homeostasis in 
obesity.65 
 
1.4.1.2.2 Hepcidin-Independent Mechanism 
Inflammation, through mediators that are separate from hepcidin 
production, may induce iron sequestration in adipose tissue and liver, thereby 
contributing to iron deficiency in obesity. mRNA expression and circulating 
concentrations of  lipocalin-2 in adipose and hepatic tissue were significantly 
increased in db/db leptin receptor deficient, obese mice compared with their lean 
littermates (P<0.001).30,66 Lipocalin-2 is an iron-binding protein that is 
upregulated by inflammation and may promote sequestration of iron during 
infections to limit bacterial growth.29,62 Therefore, inflammation may induce 
functional iron deficiency by adipose and hepatic sequestration of iron. 
 
1.4.1.3 Summary of Mechanisms Responsible for Iron Deficiency in Obesity 
In summary, obesity may increase risk for iron deficiency by 1) reducing 
iron absorption in the intestine due to high consumption of fat, 2) decreasing iron 
mobilization from the intestine and peripheral tissue via hepcidin which is induced 
by inflammation, and 3) increasing the sequestration of iron in adipose and 







1.5 Bariatric Surgery for the Treatment of Obesity 
Bariatric surgery is growing in popularity as a treatment to induce weight 
loss in patients who are moderately (body mass index, BMI ≥ 35 kg/m2) and 
severely (BMI ≥ 40 kg/m2) obese. The most recent 2013 guidelines for the 
management of overweight and obesity in adults, endorsed by the American 
Heart Association, the American College of Cardiology, and The Obesity Society, 
strongly recommend that adults with a BMI ≥ 40 or BMI ≥ 35 with obesity-related 
comorbid conditions, who are motivated to lose weight and have not responded 
to behavioral treatment, be referred to an experienced bariatric surgeon for 
evaluation.67 In addition, bariatric surgery has been implicated in the amelioration 
of comorbid cardiometabolic diseases.13,68-73 Bariatric surgery may also decrease 
risk of mechanical (arthritis and osteoarthritis, respiratory diseases and sleep 
apnea) and psychosocial (depression and eating disorders) complications of 
obesity.  
Bariatric surgery induces weight loss by altering the gastrointestinal tract 
to promote food restriction and/or malabsorption. Therefore, bariatric surgery 
promotes deficiencies in various micronutrients including iron.68 As a result, 
obese patients who choose to undergo bariatric surgery may experience the 
‘double burden’ of iron deficiency caused by pre-existing obesity, as well as 
changes in dietary intake, nutrient absorption, and inflammation following 
bariatric surgery. The risk of iron deficiency varies with each type of surgery and 
is related to the anatomical alterations that are made. The anatomical 










Figure 1.2 Anatomies of Bariatric Procedures. (A) Laparoscopic adjustable 
gastric banding. (B) Roux-en-y gastric bypass. (C) Sleeve gastrectomy. (D) 






1.5.1 Restrictive Bariatric Surgeries 
Restrictive procedures achieve weight loss by reducing stomach volume 
or absorptive capacity. The two currently-performed restrictive procedures are 
the adjustable gastric banding (AGB) and sleeve gastrectomy (SG) procedures.  
Recent 2011 data show that the former is decreasing, while the latter is growing, 
in popularity.74 
 
1.5.1.1 Adjustable Gastric Banding (AGB) 
In the AGB procedure (figure 1.2a), a band is placed around the proximal 
stomach, encompassing the upper portion of the fundus and creating a 
temporary holding pouch of 30 mL. When food is ingested, the pouch expands 
and creates intraluminal pressure, which triggers satiety signals.75 This surgery 
requires that a trained medical professional periodically tighten the band around 
the stomach to maintain the feeling of fullness. Routine band adjustment largely 
determines the effectiveness of this procedure. If the flow of food is obstructed by 
the narrowness of the band, nutritional complications, such as reflux, nausea, 
and/or vomiting may occur. AGB is associated with reduced tolerance for course-
textured foods, which may lead to the avoidance of red meats and fibrous fruits 
and vegetables.76-78 
1.5.1.2 Sleeve Gastrectomy (SG) 
In the SG procedure (figure 1.2c), the larger curvature of the stomach is 






Similar to AGB, SG achieves earlier satiety following a meal.68,79 In addition to 
reducing stomach volume, increased satiety may occur by decreases in  the 
appetitive hormone ghrelin and increases in the satiety hormone polypeptide YY 
that have been observed following SG.80 Also, SG may decrease gastric 
emptying half-time, which is the time required by the stomach to empty 50% of 
the ingested meal, as well as small bowel transit time,81 thus limiting the 
digestion, absorption, and bioavailability of some nutrients.68 
 
1.5.2 Combined Restrictive and Malabsorptive Bariatric Procedures 
Malabsorptive procedures alter the flow of food to limit contact with 
pancreatic secretions and/or bypass absorptive regions of the intestine in order 
to limit nutrient absorption.68  
 
1.5.2.1 Roux-en-Y Gastric Bypass (RYGB) 
The roux-en-y gastric bypass (RYGB, figure 1.2b) procedure is the most 
common procedure in the United States82 and combines restrictive and 
malabsorptive mechanisms. In the RYGB procedure, the stomach is reduced to a 
volume of 20-30 mL, and the food bolus is rerouted to the distal jejunum via an 
anastomosis connection.83 Although malabsorption of proteins and fats occurs at 
least initially after RYGB, restricted dietary intake plays a much larger role in the 
reduction of energy intake.84 Weight loss associated with alterations in the 






pronounced in RYGB compared to SG, as RYGB induces decreased fasting 
ghrelin concentrations, as well as increased postprandial PYY and glucagon-like 
peptide 1 (satiety hormone) concentrations.85 In addition, shunting of undigested 
food, particularly if high in simple carbohydrates or fat, directly to the lower 
jejunum, which serves as the common channel, can produce an osmotic 
imbalance that triggers severe gastrointestinal symptoms such as bloating, 
nausea, vomiting, flatulence, and diarrhea, collectively known as dumping 
syndrome. Thus, following RYGB, patients develop food intolerances and avoid 
nutrient-dense foods such as meat, milk, and foods high in fiber.76,86 
 
1.5.2.2 Biliopancreatic Diversion (BPD) 
The biliopancreatic diversion (BPD) and the more recent version, the 
biliopancreatic diversion with duodenal switch (BPD-DS, figure 1.2d), are 
primarily malabsorptive procedures, although their popularity in the United States 
and other countries is low.74 In the BPD-DS, the stomach is resected as is done 
for the SG, and then the intestine is divided at the duodenum after the pyloric 
sphincter in the proximal small intestine, and again in the distal intestine, creating 
biliopancreatic and alimentary limbs, respectively. The alimentary limb is brought 
up and connected to the duodenum, causing food leaving the stomach to bypass 
most of the small intestine. Thus, immediately following exit from the stomach, 
the food bolus is diverted and then rejoined with the biliary and pancreatic juices 






weight loss than RYGB, but is associated with more early complications and 
slightly higher perioperative mortality.87  
 
1.5.3 Consequences of Bariatric Surgery 
Poor nutritional outcomes have been associated with all weight loss 
surgeries. These may include macro- and micronutrient deficiencies as well as 
weight regain.68 In patients who experience weight regain, chronic obesity-related 
inflammation will likely persist following surgery. Notably, in the years following 
surgery the intestine adapts to improve macronutrient absorption,88 however the 
effect of gut adaptation on micronutrients has not been clearly demonstrated. 
Nutrient deficiencies may be a result of decreased dietary intake or retention of 
food following surgery, reduced absorption, or decreased bioavailability. 
 
1.5.3.1 Iron Deficiency 
Iron deficiency has been well-documented following bariatric surgery 
(postoperative prevalence: 15-54%8-12), but it is difficult to diagnose and treat due 
to its multifactorial etiology. This is partly because deficiencies in other nutrients 
may co-exist with deficiency in iron following surgery, and also that the signs and 
symptoms of iron deficiency, such as anemia, are shared with other nutrient 
deficiencies.11  
Of the common bariatric surgeries, the frequency of iron deficiency is 






deficiency in RYGB patients steadily increased from the pre-bariatric surgical 
period through the post-bariatric surgical periods; the prevalence was 5% pre-
surgery, 10% at 0-12 months, 13% at 13-24 months, and 21% at 25-36 months.93 
Similarly, clinical records of 30 patients who underwent laparoscopic RYGB 
surgery between July 2003 and January 2005 showed that the number of 
patients who presented with iron deficiency increased from 6.6% before surgery 
to 40% at 2 years and 54.5% at 3 years following surgery.11 These findings are 
consistent with others that show exacerbation of iron deficiency following 
RYGB.8,10,11,68,94-97 The range in estimates may be attributed to differences in the 
indices used, the period of time evaluated post-surgery, and the occurrence of 
iron deficiency without symptoms.68 However, symptomatic manifestations of iron 
deficiency after RYGB include hematological disorders such as chronic anemia 
and even pica, a condition associated with iron deficiency inducing unusual 
cravings for ice, cornstarch, clay, and other substances.89 Premenopausal 
women who undergo RYGB have an increased risk of iron deficiency due to 
regular blood loss during menses.68 In order to prevent iron deficiency and its 
disabling symptoms following surgery, it is important to elucidate the 
mechanisms by which iron status is reduced. 
 
1.6 Mechanisms for Iron Deficiency following Bariatric Surgery 
Changes in dietary intake, absorption, and bioavailability, due to 
mechanical alterations that are inherent to each surgical procedure, contribute to 







1.6.1 Changes in Dietary Intake 
1.6.1.1 Iron intake 
Dietary intake of iron was reported to be lower than the recommended 
amount following sleeve gastrectomy and roux-en-y gastric bypass 
surgeries.68,94,98 Decreased iron intake and retention may be related to 
gastrointestinal distress, including intolerance of iron-containing foods, as well as 
reduced availability of other nutrients whose levels are also decreased post-
surgery. Some evidence suggests that intake of meat, a good source of 
bioavailable heme iron, is reduced, which contributes to iron deficiency after 
bypass surgery 68,89 In one study, 27 out of 69 patients who had received gastric 
bypass experienced emesis (vomiting) after consuming fibrous meats.99 In 
another study, 50% of bypass patients experienced chronic meat intolerance 
after surgery.100 However, in a randomized control trial comparing bypass with 
banded patients, only the bypass patients were iron deficient, despite having 
better tolerance for eating red meat.91 Therefore, low meat intake alone may not 
explain iron deficiency in bariatric surgery patients. 
 
1.6.1.2 Intake of Nutrients Related to Iron 
Dietary intake of other nutrients, such as copper, is also important as 
these nutrients may enhance or inhibit iron absorption and metabolism. Copper is 






conversion of Fe2+ to Fe3+ so that it can be transported by transferrin into 
circulation.39 Notably, copper deficiency following bariatric surgery has been 
reported to have a prevalence ranging from 10 to 15% and an incidence ranging 
from 4 to 18%.68 Copper deficiency following surgery may result from insufficient 
copper in micronutrient supplementation and malabsorption of copper in the 
duodenum and proximal jejunum.68 Therefore, malnutrition in copper may 
contribute to iron deficiency in bariatric surgery patients. 
 
1.6.2 Reduced Iron Absorption 
Mechanisms related to anatomical alterations following bariatric surgery 
may contribute to reduced iron absorption and bioavailability. Heme and non-
heme iron absorption are reduced after SG and RYGB.101,102 
 
1.6.2.1 Diminished Gastric Acid Secretion 
Diminished gastric acid secretion and exclusion of the duodenum may 
contribute to iron malabsorption. In malabsorptive procedures the antrum is 
separated from the proximal gastric pouch, resulting in diminished gastric acid 
secretion. A longitudinal study showed a significant post-surgical decrease in 
acid secretion in eight patients who underwent gastric bypass.89,103 Reduced acid 
secretion hinders the reduction of ferric iron and ultimately absorption of ferrous 






maintain gastrointestinal continuity, have lower rates of iron deficiency than 
bypass procedures.89,104,105 
 
1.6.2.2 Duodenal Exclusion 
Excluding the duodenum from digestive continuity may also contribute to 
decreased iron absorption. Most absorption of non-heme and highly bioavailable 
heme iron occurs across duodenal enterocytes.28 Therefore, it is not surprising 
that decreasing the amount of duodenal absorptive surface area may diminish 
iron absorption following malabsorptive procedures. In support of this point, 
patients undergoing BPD-DS, which preserves some proximal duodenal function 
compared to BPD, may experience less iron deficiency.89 BPD-DS patients had 
significantly higher serum ferritin levels than BPD patients.89,106 However, a 
recent study comparing BPD and BPD-DS found no significant difference in 
serum iron levels.89,107 Additional information is needed to draw conclusions 
because serum iron is not a good indicator of iron status.  
 
1.6.2.3 Decreased Duodenal Absorptive Capacity 
In addition to decreasing duodenal absorptive capacity, malabsorptive 
procedures delay interaction between pancreatic enzymes and biliary secretions 
and the food bolus until the common channel. This has a pronounced adverse 
effect on heme iron absorption, as biliopancreatic secretions are necessary for 






heme that is available for absorption.89,108 Therefore, incomplete digestion of 
heme iron may exacerbate iron malabsorption. 
 
1.6.3 Inflammation 
1.6.3.1 Bacterial Overgrowth 
Inflammation caused by bacterial overgrowth may reduce iron 
bioavailability via mechanisms similar to obesity-related inflammation. 
Malabsorptive bariatric surgery may induce bacterial overgrowth and 
inflammation in the functional and remnant stomach.82 In a prospective 
observational study of 35 RYGB patients who had predominantly normal gastric 
endoscopic findings before surgery, 74.3% developed various types of gastritis, 
or inflamed lining of the stomach, almost exclusively in the excluded stomach.109 
Also, in post-RYGB subjects, high microbial counts were detected in 59.5% of 
samples from the functional gastric pouch and 18.9% of samples from the 
excluded reservoir.110 Infection by Helicobacter pylori was correlated with 
bacterial overgrowth.110 Therefore, inflammation due to bacterial overgrowth may 
contribute to iron deficiency following bariatric surgery. 
 
1.6.3.2 The Inflammation Discrepancy 
A paradoxical impact of bariatric surgery is that although it appears to 
impair iron status, it also promotes long-term weight loss, thereby ameliorating 






Following bariatric surgery, reductions in BMI, CRP, IL-6, and orosomucoid are 
well-documented.111,112,113 One study showed a significant increase in transferrin 
saturation at six months following surgery, which the authors attributed to the 
reduction of inflammation, as CRP and orosomucoid were inversely correlated 
with transferrin saturation before and after surgery.113 This data suggests that 
bariatric surgery-induced weight loss is associated with reduction of inflammation 
and improvement in functional iron status in these patients. However, this finding 
is in contrast to the findings of several studies that show exacerbation of iron 
deficiency up to three years following RYGB.11,93 Therefore, there may be other 
factors that may explain the discrepancy, such as the time that has elapsed since 
surgery. 
 
1.7 Research Questions 
With the increasing trend of severe obesity, there is an increase in the 
number of bariatric procedures performed worldwide.114 RYGB is the most 
commonly performed bariatric procedure.114 A high prevalence of iron deficiency 
is documented following RYGB (10-45%).8,10,11,94-97 Hemoglobin concentrations 
were significantly lower in patients receiving gastric bypass than in restrictive 
bariatric surgeries115 and prevalence of anemia as high as 64% has been 
reported following RYGB.11,96,115-119 A well-established mechanism for iron 
deficiency following RYGB shown by Ruz et al is reduced iron absorption.101,102 
Other suggested mechanisms include reduced intake of iron and other nutrients 






inflammation. Chapter 2 describes studies in which we document the high 
prevalence of iron deficiency and the associated clinical manifestation of anemia 
following RYGB as well as explore some mechanisms responsible. Our overall 
objective was to describe iron homeostasis following RYGB by using 
comprehensive screening approach to assess micronutrient status, dietary intake, 
and anemia in RYGB patients. The first aim was to conduct a comprehensive 
screening of nutrients involved in iron homeostasis in RYGB patients. We 
hypothesized that iron deficiency occurs in combination with other nutrient 
deficiencies. The second aim was to determine the contribution of dietary intake 
to the micronutrient profile of RYGB patients. We hypothesized that low intake of 
iron and intake of nutrients involved in iron homeostasis from diet and 
supplements contributes to malnutrition in iron following RYGB. The third aim 
was to describe associations between anemia and nutritional status in RYGB 
patients. We hypothesized that anemia is associated with iron deficiency as well 
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Roux-en-Y gastric bypass surgery (RYGB) is effective for weight loss, but 
is commonly associated with iron deficiency and its clinical manifestation, anemia. 
Diagnosing iron deficiency is complex because iron status depends on other 
nutrients; additionally, anemia following surgery is not specifically due to 
deficiency in iron, as it can be due to deficiencies in other nutrients including zinc, 
copper, vitamin B6, folate, and vitamin B12. In patients who have undergone 
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients 
involved in iron homeostasis, 2) determine the contribution of dietary intake to 
iron deficiency, and 3) describe associations between anemia and nutritional 
status of iron and other nutrients. Systemic measures of hemoglobin, ferritin, 
serum transferrin receptor (sTfR), total iron binding capacity (TIBC), copper (Cu), 
vitamins B6 and B12, folate, zinc (Zn), and C-reactive protein (CRP) were 
determined using reference methods. Iron deficiency equaled having ≥ 2 
abnormalities in: ferritin, sTfR, sTfR:ferritin, or TIBC. Ferritin, a measure of iron 
stores, was defined as normal (ferritin ≥ 20 mcg/L) or low (ferritin < 20 mcg/L). 
Statistics included prevalence, mean ± standard error of the mean (s.e.m.) for 
normally-distributed data, median ± semi-interquartile range for skewed data 
(indicated with an asterisk [*]), frequency tables, t-tests (independent, by group), 
correlations, and general linear models (significant if p < 0.05). Subjects (N=70) 
were 91% female, age 49 ± 1 years, *4 ± 2 years post surgery, and 79% 
Caucasian. Fifty-six percent of the total population and 96% of the subpopulation 






deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12. The most 
prevalent nutrient deficiencies in the total population and the subpopulation with 
anemia were iron and zinc; prevalence of iron and zinc deficiency in the total 
population was 24.3% and 20.0%, respectively, and prevalence of iron and zinc 
deficiency in the subpopulation with anemia was 46.2% and 23.1%, respectively. 
Participants in the total population and the subpopulation with anemia were also 
deficient in copper, vitamin B6, vitamin B12, and folate (11.5% and 26.9%, 
respectively). In the total population, iron and zinc deficiency occurred in isolation 
and also in combination with other nutrient deficiencies; all other nutrient 
deficiencies occurred in combination. In the subpopulation with anemia, only iron 
deficiency occurred in isolation. The dietary intake of the study population 
exceeded the RDAs for all nutrients assessed.  In addition, patients with low 
ferritin concentrations consumed lower total energy (p= 0.009), fat (p= 0.026), 
protein (p=0.013), and animal protein (p=0.023), compared to patients with 
normal ferritin concentrations. Dietary intake of heme iron was correlated with 
years post-RYGB surgery (r=0.67, p<0.05). In conclusion, in a community-based 
surveillance of RYGB patients we found that, more often than not, RYGB patients 
presented with micronutrient deficiencies related to iron nutriture; this includes 
deficiencies in iron, copper, zinc, vitamin B6, folate, and vitamin B12. It was more 
likely for multiple deficiencies to occur simultaneously than for deficiencies to 
occur alone. In addition, there was a high prevalence of anemia, a clinical 
manifestation of deficiencies in these nutrients. Implications of these findings are 






with known symptoms or manifestations of iron deficiency, should also screen 
patients for deficiencies in copper, zinc, vitamin B6, folate, and vitamin B12, as 
these deficiencies are also prevalent following surgery, may occur 
simultaneously with iron deficiency, and are also implicated in anemia. Based on 
our findings that RYGB patients who have more favorable iron stores consume 
more energy, fat, and protein than patients with low iron stores, increasing 
protein intake following surgery may improve iron status; although, increasing 
consumption of fat may have detrimental effects on weight regain in the RYGB 
population. Findings of this study may be used to enhance prophylactic 
measures and treatments for iron deficiency following RYGB.  
 
2.3 Introduction 
The rate of obesity (BMI > 30 kg/m2) is increasing; in particular, there is an 
increasing trend in the severely obese category (BMI ≥ 40 kg/m2).2 Bariatric 
surgery is an effective treatment for weight loss, as well as the improvement or 
resolution of obesity-related comorbidities including diabetes, hyperlipidemia, 
hypertension, and obstructive sleep apnea.120 Therefore, it is not surprising that 
as the number of severely obese persons increases, there is a parallel increase 
in the number of bariatric procedures performed worldwide.114 The roux-en-y 
gastric bypass (RYGB) procedure is the most commonly performed bariatric 
procedure in the United States82 and combines restrictive and malabsorptive 
mechanisms that promote weight loss. In the RYGB procedure, the stomach is 






jejunum via an anastomosis connection83; therefore, patients who undergo RYGB 
are vulnerable to nutrient deficiencies due to restricted food intake and 
malabsorption of nutrients. 
There is a high prevalence of iron deficiency in obese individuals who are 
candidates for bariatric surgery (28%-35%)5-7 and following RYGB (10-
45%).8,10,11,94-97 Iron deficiency is the most common and widespread nutritional 
disorder in the world, and the only nutrient deficiency that is significantly 
prevalent in industrialized nations.13,14 Iron deficiency is associated with 
increased infant mortality and perinatal risks for mothers and neonates, and 
adversely affects cognitive performance, behavior, and physical growth of infants 
and adolescents. Iron deficiency also impairs immune status, increases morbidity 
from infections, and reduces physical capacity and work performance in all age 
groups.13 Severe iron deficiency is associated with low blood concentrations of 
hemoglobin, and is termed iron deficiency anemia (IDA).13 Reported mechanisms 
that may contribute to the high prevalence of iron deficiency following RYGB 
include reduced heme and non-heme iron absorption101 and reduced dietary iron 
intake.94,98 
Assessment of iron status is complex. First, iron status depends on other 
nutrients, such as copper- which is involved in iron absorption via the enzyme 
hephaestin, vitamin B6 and zinc- which are involved in heme synthesis, and 
vitamin B12 and folate- which are needed for blood cell differentiation. Second, it 
is possible that deficiencies in multiple nutrients which impact iron status may 






there is a lack of evidence in the literature. Finally, the widely known clinical 
manifestation of iron deficiency, anemia (low hemoglobin), adds to the complexity 
of diagnosing iron deficiency. Anemia is observed after RYGB with a prevalence 
as high as 64%.11,94,113-117 However, anemia following surgery is not specific to 
deficiency in iron alone, as it can be due to deficiencies in other nutrients 
including copper, folate, vitamin B12, zinc, and vitamin B6.  
To our knowledge, no one has explored the reasons for and 
consequences of the poor iron homeostasis observed following RYGB by 
describing micronutrient status, dietary intake, and anemia associated with the 
various nutrients implicated in iron nutriture. In patients who have undergone 
RYGB, our aims were to 1) conduct a comprehensive assessment of nutrients 
involved in iron homeostasis, 2) determine the contribution of dietary intake to 
iron deficiency, and 3) describe associations between anemia and nutritional 
status of iron and other nutrients. Findings of this study will be significant as they 
may be used to enhance prophylactic measures and treatments for iron 
deficiency following RYGB. 
 
2.4 Patients and Methods 
We used a marketing database to obtain addresses in the Greater 
Lafayette, IN community and recruited participants by mailing information about 
the study. Recruiting participants from the community and randomly selecting 






obtained their surgical procedures at various clinics and who had various lengths 
of elapsed time since surgery. 
 
2.4.1 Study Population 
The study began May of 2012. During recruitment, participants were pre-
screened by telephone. They were eligible for screening if they underwent RYGB 
at least 6 months prior, and were 18-65 years of age. After August 2013, we 
added the additional criterion that participants must be currently experiencing 
anemia, and we also began to administer a three-day food record to each eligible 
participant to complete prior to the screening visit.  
 
2.4.2 Metabolic Measures 
We did a comprehensive screening of nutrients related to iron 
homeostasis. Plasma samples were obtained at screening and stored at -80°C. 
Ceruloplasmin activity and serum transferrin receptor were measured in-house. 
Ceruloplasmin activity was measured using the oxidase method.121 The 
coefficients of variation for the intra- and inter-assay variability were 3.6% and 
3.8%, respectively. Soluble serum transferrin receptor was measured using the 
enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). 
Copper, ferritin, zinc, vitamins B1, B6, B12, folate, hemoglobin, TIBC, and C-
reactive protein were commercially measured by Mid America Clinical 
Laboratories (MACL), Indianapolis, IN, USA. Serum copper and zinc were 






Vitamin B1 from whole blood and serum vitamin B6 were measured using liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS). Serum 
ferritin was measured using a Chemiluminescent Microparticle Immunoassay 
(CMIA). Serum vitamin B12 and folate were measured using chemiluminescence. 
Siemens Advia 2120i instrumentation was used by MACL to perform hemoglobin 
analysis. TIBC was measured using the tripyridyltriazine/ferine method. CRP was 
measured using the turbidimetric latex method. 
Subjects were found to be deficient in iron if they met at least two of the 
following four conditions: TIBC > 370 mcg/dL (cutoff determined by MACL), 
serum ferritin < 20 mcg/L,122,123 serum transferrin receptor (sTfR) > 28.1 nmol/L, 
sTfR:ferritin ratio > 500.122 Subjects were found to be anemic if hemoglobin < 12 
g/dL in menstruating women and hemoglobin < 13 g/dL in men and post-
menopausal women.13 Deficiencies in other nutrients were defined as copper 
(serum copper < 70 mcg/dL determined by MACL; ceruloplasmin < 62.5 U/L121), 
zinc < 60 mcg/dL, vitamin B6 < 2.1 ng/mL, folate <5.4 ng/mL and vitamin B12 < 
220 pg/mL. Inflammation, measured by cardio C reactive protein (CRP), was 
abnormally high if > 3.1 mg/L (cutoffs determined by MACL). 
 
2.4.3 Dietary Analysis 
Nine participants completed three-day food records, for which we 
performed dietary analysis using Nutrition Data System for Research (NDSR); 
software (University of Minnesota, Minneapolis, MN, USA). The daily intake of 






iron was calculated by multiplying the number 0.4 by the total iron content of all 
meat items. 
 
2.4.4 Statistical Analysis 
The statistical software STATISTICA (StatSoft Inc., Tulsa, OK, USA) was 
used for analysis. Descriptive statistics were assessed using parametric tests 
and expressed as mean ± standard error of the mean (s.e.m.) for normally 
distributed data and median ± semi-interquartile range for skewed data. Values 
presented as median ± semi-interquartile range are indicated with an asterisk (*). 
Prevalence of micronutrient deficiencies were determined and defined as the 
number of cases of each micronutrient deficiency; the denominator was 70 
subjects for the total population, 26 subjects for the population with anemia, and 
nine subjects for the population with dietary records. Differences between 
categorical groups were determined using independent t-tests; associations 
between nutrient status and continuous variables (such as dietary intake and 
blood concentrations of micronutrients) were determined using independent t-
tests, by group. Pearson correlations between continuous variables were 
performed. We had the capability of using general linear models to determine 
potential interactions between covariates if we found significant correlations 
between variables; however, we found no correlations between variables of 
interest. Differences in prevalence of deficiency between populations were 








2.5.1 Population Characteristics 
Table 2.1 shows the population characteristics for the total population, the 
subpopulation with anemia, and the subpopulation with completed three-day food 
records. In the total population, 70 eligible patients were assessed. The 
population was 91% female, 79% Caucasian and 14% African American. At the 
time of screening, subjects were 49.4 ± 0.9 years of age and were *4 ± 2 years 
post-RYGB surgery. The average BMI in the total population was *28.9 ± 2.7 
kg/m2. Fifty-one percent of the subjects in the total population reported taking 
multivitamin/multimineral supplements and 10% reported not taking these 
supplements; thirty-nine percent of the total population did not provide this 
information. 
The subpopulation with anemia included 26 RYGB patients. The 
population was 100% female, 75% Caucasian and 25% African American. At the 
time of screening, subjects were 50.3 ± 1.2 years of age and were *4 ± 2 years 
post-RYGB surgery. The average BMI in the population with anemia was *26.4 ± 
2.5 kg/m2. Fifty percent of the subjects in the population with anemia reported 
taking multivitamins and 12% reported not taking multivitamins; thirty-eight 
percent of the subpopulation with anemia did not provide this information.  
The subpopulation with three-day food records included nine RYGB 
patients. The population was 89% female and 100% Caucasian. At the time of 
screening, subjects were 48.0 ± 2.6 years of age and 5.4 ± 1.7 years post-RYGB 






kg/m2. Seventy-eight percent of the subjects in the population with dietary 
records reported taking multivitamins and 22% reported not taking multivitamins. 
 
2.5.2 Nutrient Deficiencies 
Table 2.2 shows the prevalence of deficiency for nutrients involved in iron 
homeostasis in the total population, the subpopulation with anemia, and the 
subpopulation with dietary records. In 55.7% of the total population, we found 
deficiencies in nutrients related to iron nutriture. Prevalence of deficiency in the 
total population for iron (Fe), zinc (Zn), copper (Cu), vitamin B6 (B6), folate (Fol), 
and vitamin B12 (B12) from highest to lowest were: Fe= 24.3%, Zn= 20.0%, B6= 
4.3%, Cu= 2.9%, B12= 2.9% and Fol= 1.4%. In 44.3% of the total population we 
did not find deficiencies related to iron homeostasis. 
Prevalence of anemia in the total population was 37.1%. In 96.2% of the 
subpopulation with anemia, we found deficiencies in nutrients related to iron 
nutriture. Prevalence of deficiencies in the subpopulation with anemia from 
highest to lowest were: Fe= 46.2%, Zn= 23.1%, Cu= 7.7%, B6= 7.7%, B12= 7.7%, 
and Fol= 3.8%. In 3.8% of the participants with anemia we did not find 
deficiencies related to iron homeostasis. There was a significantly higher number 
of participants with iron deficiency in the subpopulation with anemia compared to 
the total population (p= 0.04). There was no significant difference in the number 
of participants with zinc, copper, vitamin B6, folate, or vitamin B12 deficiencies 






Prevalence of deficiencies in the subpopulation with three-day food 
records from highest to lowest were: Fe= 22.2%, Zn= 11.1%, Cu= 11.1%, B6= 
0%, Fol= 0%, and B12= 0%. Prevalence of anemia in the subpopulation with 
three-day food records was 44.4%. In 55.5% of the population with dietary 
records we did not find deficiencies related to iron homeostasis.  
Figure 2.1 shows that patients in the total population experienced isolated 
deficiencies (deficiencies occurring alone) and combined deficiencies (multiple 
deficiencies occurring simultaneously) in nutrients involved in iron homeostasis. 
In the total population, iron and zinc deficiency occurred in isolation as well as in 
combination with other micronutrient deficiencies. Iron deficiency occurred in 
isolation (prevalence 19%) and in combination with deficiencies in zinc and 
vitamin B12 (prevalence 6%). Zinc deficiency occurred in isolation (prevalence 7%) 
or combined with deficiencies in other nutrients, including iron, copper, vitamin B6, 
folate, and vitamin B12 (prevalence 13%). Deficiencies in the other nutrients 
(copper, vitamin B6, folate, and vitamin B12) occurred in combination with other 
nutrient deficiencies only.  
Figure 2.2 shows that patients in the population with anemia experienced 
isolated and combined deficiencies in nutrients implicated in iron homeostasis 
and anemia. There was a higher prevalence of deficiencies in nutrients other 
than iron, but that were still involved in iron homeostasis and metabolism, than 
iron deficiency. Participants with anemia presented with isolated iron deficiency 
(prevalence 35%), as well as iron deficiency combined with deficiencies in zinc 






were present in combination only (prevalence 49%); nutrients included zinc, 
vitamin B6, folate, vitamin B12 and copper. In 4% of the population with anemia 
(one participant), we did not detect any deficiencies in nutrients related to iron 
nutriture. 
Normal or deficient status of iron, zinc, copper, vitamin B6, folate, or 
vitamin B12 was not associated with the number of years since surgery. 
Concentration of iron, zinc, copper, vitamin B6, folate, or vitamin B12 was not 
correlated with the number of years since surgery. 
 
2.5.3 Blood Cell Size in Participants with Anemia 
Within the subpopulation with anemia, 15% of participants presented with 
microcytic anemia (MCV < 78 fL) and 85% presented with normocytic anemia 
(MCV 78-100 fL). Of the four participants with microcytic anemia, one was 
deficient in iron only, one was deficient in zinc only, one was deficient in iron and 
zinc only, and in one patient we did not assess micronutrient deficiencies. 
 
2.5.4 Dietary Intake 
The average intakes of macronutrients, as well as micronutrients that 
impact iron absorption and homeostasis are shown in Table 2.3. On average 
patients reported a daily intake of total energy= 1650.4 ± 605.1 kcal, total fat= 
66.5 ± 10.2 g, total protein= 77.9 ± 9.8 g, animal protein= 57.8 ± 8.6 g, and total 
carbohydrate= 189.8 ± 28.9 g. Daily micronutrient intake averaged total iron= 






copper= 2.6 ± 0.9 mg, zinc= 19.7 ± 5.3 mg, calcium= 1407.8 ± 341.0 mg, vitamin 
C= 108.0 ± 30.6 mg, vitamin B6= 3.1 ± 0.8 mg, folate= 594.2 ± 169.1 mcg, and 
vitamin B12= 119.8 ± 112.5 mcg. This population, on average, exceeded the 
RDAs for all nutrients assessed, including vitamin C which enhances iron 
absorption, and calcium which inhibits iron absorption. However, we did not find 
significant associations or correlations between micronutrient intake and iron 
status. 
We found associations between intake of macronutrients and iron status. 
Total energy intake (p= 0.009), as well as fat (p= 0.026), protein (p=0.013), and 
animal protein (p=0.023), was higher in subjects with normal compared to low 
ferritin status (Figure 2.3). We did not find significant associations between iron 
status (overall iron deficiency status, and status of iron deficiency measured by 
ferritin, TIBC, sTfR and sTfR:ferritin ratio) or anemia, and dietary intake of total 
iron, heme iron, or non-heme iron (data not shown). Dietary heme iron intake 
was correlated with years post-RYGB surgery (r=0.67, p<0.05; figure 2.4); for 
each increase in years post surgery, dietary iron intake increased by 0.67 ± 0.28 
mg. There was no association between meat servings and iron status. There 
were no associations between intake of other micronutrients or macronutrients 
and time following surgery. 
 
2.6 Discussion 
In summary, our main findings were that following RYGB, more than half 






including deficiencies in iron, zinc, copper, vitamin B6, folate, and vitamin B12; 
prevalence of deficiency was not related to the number of years since surgery. Of 
importance, simultaneous deficiencies were common. Notably, of the isolated 
deficiencies, iron was most prevalent. Similarly, patients with anemia had 
isolated iron deficiency as well as simultaneous deficiencies in iron, zinc, copper, 
vitamin B6, folate, and vitamin B12; deficiencies in nutrients other than iron were 
more common than isolated iron deficiency in the subpopulation with anemia. In 
addition, RYGB patients, on average, exceeded the RDAs for nutrients involved 
in iron homeostasis, as well as nutrients known to inhibit iron absorption; 
however, there was no association between the intake of micronutrients and iron 
status or anemia. RYGB patients with low iron stores (indicated by ferritin 
concentrations) consumed less total energy, fat, protein, and animal protein than 
patients with normal iron stores, suggesting that the intake of macronutrients had 
a greater impact on iron status than the intake of micronutrients. Finally, dietary 
heme iron intake increased with time following RYGB surgery, suggesting that 
gastric bypass patients consume more meat further out from surgery. 
Consistent with recent literature, we have documented deficiencies in 
iron,8,10,11,94-97,124 zinc,125 copper,126 vitamin B12,
124 folate,124 and vitamin B6
127 
following RYGB. Compared to recent studies, most of which have followed 
RYGB surgery cohorts for up to two years post-surgery,124-126 our findings show 
the prevalence of deficiencies in nutrients implicated in iron homeostasis in 
RYGB patients who are, on average, five years post-surgery. Since we 






of deficiency may be lower, compared to other studies, for nutrients such as 
folate= 15%,124 vitamin B12= 50%,
124 vitamin B6= 18%,
127 and copper= 10%.126 
However, it is also difficult to compare prevalence between studies because of 
the variability in cutoffs and methods used in measuring micronutrients. Another 
theory is that the status of nutrients may increase with lessened food intolerance 
in the years following surgery; however, our findings suggest that micronutrient 
status is not associated with the time that has elapsed since surgery.  
Other novel findings from the current study are the combinations in which 
these deficiencies are presented, both in the general RYGB population and in 
RYGB population with anemia. Iron deficiency and its clinical manifestation, 
anemia, can occur simultaneously with deficiencies in other nutrients, including 
zinc and B vitamins. Also, in addition to iron deficiency, patients with anemia 
presented with deficiencies in copper, zinc, vitamin B6, folate and vitamin B12. 
Therefore, iron deficiency may mask these other forms of malnutrition if it is the 
only nutrient that is measured. The occurrence of simultaneous deficiencies also 
makes it difficult to use MCV to differentiate between the types of anemia. Eighty-
five percent of the population with anemia presented with normocytic anemia, 15% 
presented with microcytic anemia (generally attributed to deficiencies in iron, 
copper, vitamin B6, and zinc), and no patients presented with macrocytic anemia 
(generally associated with megaloblastic anemias of folate and vitamin B12. It is 
possible that most of our patients presented with normocytic anemia because 
having microcytic and macrocytic anemias simultaneously may blunt the 






normal cell size. More specific tests are needed for accurate differentiation; 
examining megalocytes and segmented neutrophils on a peripheral blood smear 
may better detect megaloblastic anemias. 
We found a significant positive correlation between dietary heme iron 
intake and the number of years post-surgery. This finding suggests that 
participants who were further out from surgery consumed more heme iron, which 
is found in meat products. Initially, this appeared to be inconsistent with findings 
of meat intolerance with little improvement up to seven years post-surgery100; 
however, after removing time points greater than seven years post-surgery from 
our study population, heme iron intake was no longer associated with the number 
of years post-surgery. Therefore, heme iron intake may initially increase with the 
increase in time following surgery (up to seven years), but heme iron intake may 
ultimately plateau. Although heme iron is normally considered to be the more 
bioavailable form of iron, malabsorptive procedures delay interaction between 
pancreatic enzymes and biliary secretions and the food bolus until the common 
channel. This has a pronounced adverse effect on heme iron absorption, as 
biliopancreatic secretions are necessary for proteolytic digestion of myoglobin 
and hemoglobin, and ultimately the release of heme that is available for 
absorption.89,108 This phenomenon may account for why iron status did not 
improve with the increase in heme iron take, and why iron status did not improve 
with time following surgery. 
Our patient population exceeded the RDAs for all nutrients assessed, 






However, the 2013 Update of the Clinical Practice Guidelines for the 
Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric 
Surgery Patient recommends that RYGB patients take two adult multivitamin plus 
mineral supplements daily.128 The guidelines further specify minimum daily 
supplementation of 45-60 mg iron, 2 mg of copper, 400 mcg of folate, and 1000 
mcg of vitamin B12. There were no specific recommendations for vitamin B6 and 
zinc. Our study population did not reach these recommended supplementation 
levels for iron or vitamin B12. However, we found no association between the 
intake of micronutrients and iron status or anemia, which suggests that the intake 
of micronutrients may not be used to predict or treat iron deficiency or anemia. 
A notable strength of this study was recruitment from the community, 
rather than from one bariatric center, which is typical in the literature. Recruiting 
participants from the community afforded us a representative sample of bariatric 
surgery patients who obtained their surgical procedures at various clinics, who 
had various lengths of elapsed time since surgery, and who had different dietary 
recommendations following surgery. This representative RYGB population 
sample enabled us to accurately measure the true prevalence of nutrient 
deficiencies and dietary intake. A limitation was that our study was cross-
sectional. As a result, we cannot infer any incidence or cause-and-effect 
relationships; we can only present associations. Another limitation of our study 
was our sample size for the subpopulation with three-day food records; the low 
number of participants in this group may explain the lack of association between 






Although iron deficiency is prevalent following RYGB, there are patients 
who remain normal in iron status. Therefore, our goal was to investigate other 
factors that may affect iron status following surgery, including the status and 
dietary intake of other nutrients implicated in iron homeostasis. In support of this 
goal, we found that there were deficiencies in micronutrients involved in iron 
absorption (copper), heme synthesis (vitamin B6 and zinc) and blood cell 
differentiation (vitamin B12 and folate). We found that combinations of 
deficiencies in these nutrients were more prevalent than isolated iron deficiency. 
Additionally, we found that dietary intake of energy, fat, total protein, and animal 
protein were lower in individuals with low iron stores compared to individuals with 
normal iron stores. Finally, we found that patients consumed more heme iron the 
further they were out from surgery. Comprehensive screening of micronutrient 
status following RYGB surgery is needed in order to uncover defects in iron 
nutrition following RYGB. Also, increasing consumption of foods with high 
content of calories, fat and protein may predict a more favorable iron status, but 
may have undesirable effects on other surgery outcomes such as weight regain. 
These findings may be used to guide further investigation and develop 






Table 2.1 Population Characteristics 
Parameters Total Population Population with 
Anemia 
Population with Dietary 
Records 
Sample Size N=70 N=26 N=9 
% Female 91 100 89 
Race/Ethnicity  
(% White: Black: Other) 
79: 14: 1 75: 25: 0 100: 0: 0 
Age in Years (range) 49.4 ± 0.9 (30 to 65) 50.3 ± 1.2 (35 to 61) 48.0 ± 2.6 (30 to 58) 
Years Post Surgery (range) *4 ± 2 (0 to 33) *4 ± 2 (0 to 12) 5.4 ± 1.7 (0 to 14) 
BMI (kg/m2) (range) *28.9 ± 2.7 (18.2 to 61.1) *26.4 ± 2.5 (21.0 to 61.1) *26.5 ± 2.7 (22.3 to 45.0) 
Multivitamin Use  
(% Yes: No: Missing) 
51: 10: 39 50: 12: 38 78: 22: 0 
Table 2.1 shows the population characteristics for the total population of screened RYGB participants, the subpopulation 
with anemia, and the subpopulation with completed dietary records. Age in Years, Years Post Surgery, and BMI reported 







Table 2.2 Prevalence of Deficiencies 
Type of Deficiency Total Population 
(N=70) 
number: prevalence 







Iron deficiency 17: 24.3% 12: 46.2% 2: 22.2% 
Zinc deficiency 14: 20.0% 6: 23.1% 1: 11.1% 
Copper deficiency 2: 2.9% 2: 7.7% 1: 11.1% 
Vitamin B6 deficiency 3: 4.3% 2: 7.7% 0 
Folate deficiency 1: 1.4% 1: 3.8% 0 
Vitamin B12 deficiency 2: 2.9% 2: 7.7% 0 
No deficiency or deficiency 
in other nutrients 
31: 44.3% 1: 3.8% 5: 55.5% 
Table 2.2 shows the types and prevalence of nutrient deficiencies related to iron homeostasis in the total screened RYGB 










Figure 2.1. Combined deficiencies in nutrients related to iron homeostasis in the 
total population (N=70). Abbreviations: Fe= iron, Cu= copper, Zn= zinc, B6= 










Figure 2.2. Combined deficiencies in nutrients related to iron homeostasis in the 
subpopulation with anemia (N=26). Abbreviations: Fe= iron, Cu= copper, Zn= 











Table 2.3 Mean daily dietary intake of post-RYGB patients 
Variables Mean ± S.E.M. % RDA for average 
participant: 
(Female, Age 31-50) 
Total Energy (kcal) 1650.4 ± 605.1 - 
Total Fat (g) 66.5 ± 10.2 - 
Total Protein (g) 77.9 ± 9.8 - 
Animal Protein (g) 57.8 ± 8.6 - 
Total Carbohydrate (g) 189.8 ± 28.9 - 
Total Iron (mg) 41.8 ± 18.2 232.2% 
Heme Iron (mg) 0.85 ± 0.18 - 
Non-heme Iron (mg) 40.9 ± 18.3 - 
Vitamin B6 (mg) 3.1 ± 0.8 238.5% 
Folate (mcg) 594.2 ± 169.1 148.6% 
Vitamin B12 (mcg) 119.8 ± 112.5 4991.6% 
Vitamin C (mg) 108.0 ± 30.6 144.0% 
Copper (mg) 2.6 ± 0.9 288.9% 
Zinc (mg) 19.7 ± 5.3 246.2% 
Calcium (mg) 1407.8 ± 341.0 140.8% 
Table 2.3. Dietary intake was analyzed using NDSR software. Average ± S.E.M. 
was determined using STATISTCA software. The %RDA was calculated using 










Figure 2.3. Associations between ferritin status as mean total energy, total fat, total protein, and animal protein in nine 
RYGB patients. Normal ferritin status (dark grey bars) was defined as ferritin ≥ 20 mcg/L and deficient ferritin status (light 










Figure 2.4. Correlation (r=0.67, p<0.05) between dietary heme iron intake and years post-RYGB surgery in nine 
participants. Heme iron was calculated by multiplying the iron content in meat products by 0.4. The dashed lines represent 







CHAPTER 3. CONCLUSIONS 
3.1 Conclusions 
Fifty-six percent of the total RYGB study population presented with 
micronutrient deficiencies related to iron nutriture; this includes deficiencies in 
iron, copper, zinc, vitamin B6, folate, and vitamin B12. This suggests that, more 
often than not, patients will present with one or more deficiencies in nutrients that 
affect iron status post-operatively. In addition, there is a high prevalence of 
anemia (37%) in the RYGB population, which would be expected since 
deficiency in iron and iron-related nutrients are so common. Of importance, 
RYGB patients more commonly present with multiple deficiencies simultaneously 
in nutrients related to iron homeostasis than with iron deficiency alone. Therefore, 
it is vital that health providers for RYGB patients routinely perform 
comprehensive assessments of micronutrient status, which includes iron as well 
as zinc, copper, and the B vitamins, in order to detect and effectively treat iron 
deficiency and anemia following surgery.  
Dietary intake of iron (heme or non-heme) or of other micronutrients did 
not appear to affect iron status or anemia. Therefore, it may not be effective to 
make dietary recommendations to increase intake of iron and related nutrients 







this must be confirmed in future studies. However, patients with normal ferritin 
concentrations had a higher consumption of total energy, fat, protein, and animal 
protein than patients with low ferritin concentrations. Although a more favorable 
iron status is associated with higher fat consumption, recommending higher fat 
consumption may have undesirable effects; increasing dietary fat consumption 
may contribute to weight regain in the bariatric surgery population, as dietary fat 
induces overconsumption and weight gain in obese and post-obese subjects.129 
However, it may be worthwhile to recommend a high-protein diet in RYGB 
patients to improve iron status. Since we found that heme iron intake increases 
with time following surgery, it appears plausible to increase animal protein (found 
in meat, which is the primary source of heme iron) in the years following surgery. 
However, if patients are intolerant to animal protein in the immediate period 
following surgery, other forms of protein supplementation may be needed in 
order to improve iron status in these patients. 
Our findings supported our hypothesis that iron deficiency occurs in 
combination with deficiencies of other nutrients that effect iron status. These 
nutrients include vitamin B12 and zinc. However, RYGB patients also presented 
with iron deficiency alone, zinc deficiency alone, or multiple deficiencies in 
nutrients excluding iron. Our findings did not support our hypothesis that dietary 
intake of iron or other nutrients involved in iron homeostasis is an important 
factor in determining iron status. Instead, our preliminary data suggests that 
macronutrient, rather than micronutrient, intake impacts iron status. Our findings 







as deficiencies in other nutrients following RYGB. RYGB patients with anemia 
also experienced multiple deficiencies simultaneously more often than they 
experienced iron deficiency alone.   
Implications of these findings are that clinicians who evaluate post-RYGB 
patients, especially patients who present with known symptoms or manifestations 
of iron deficiency, should include copper, zinc, vitamin B6, folate, and vitamin B12 
in their assessment. Although the latest Clinical Practice Guidelines for the 
Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric 
Patient recommends postoperative evaluation of iron, zinc, and vitamin B12, there 
are no recommendations for assessment of copper, folate, or vitamin B6. For 
post-bariatric patients with anemia, these guidelines suggest evaluating vitamin 
B12, folate, copper, and zinc only if routine screening for iron deficiency is 
negative;128 this does not take into account the occurrence of multiple 
deficiencies simultaneously, which was shown by this study to be more prevalent 
than the occurrence of any deficiency in isolation. Even if a patient tests positive 
for iron deficiency, this does not rule out the possibility of simultaneous 
deficiencies in other nutrients. Therefore, failing to perform comprehensive 
assessment of all nutrients and/or treating some deficiencies and not others will 
not effectively treat these patients. Routine, comprehensive screening is 
important for prevention, accurate diagnosis, and effective treatment of 








3.2 Future Directions 
In the future, it would be beneficial to increase the number of participants 
with dietary records. This will allow us to have more definitive information 
regarding associations between dietary intake and iron status. We would also like 
to develop the appropriate micronutrient formula to effectively treat iron 
deficiency through supplementation. Our preliminary findings have suggested 
that RYGB patients exceed the RDA for intake of iron and related nutrients; 
however, RYGB patients are at higher risk for micronutrient deficiencies than the 
normal population. In support of this, the guidelines for bariatric surgery patients 
recommend that RYGB patients take two multivitamin plus mineral supplements 
daily, although they do not specify recommended intake of all nutrients related to 
iron nutriture.128 Thus, future studies are needed to determine effective doses of 
iron and other nutrients involved in iron homeostasis. Also, it would be useful to 
assess dietary intake of phytates and polyphenols that are known to inhibit iron 
absorption, in order to more thoroughly investigate the impact of food 
constituents on iron status.  
Additionally, we are in the process of developing an in-house method for 
simultaneously quantifying water-soluble vitamins from plasma samples using 
mass spectrometry. This is a potential cost effective method that may be used to 
perform comprehensive analysis of nutrients involved in iron homeostasis, such 
as the B vitamins.  We hope that lowering the cost of micronutrient assessment 
will facilitate the comprehensive screening that we propose will benefit the RYGB 







Finally, recent evidence suggests that polymorphisms in genes that 
regulate iron absorption and mobilization promote iron deficiency. Single 
nucleotide polymorphisms (SNP)s in the transferrin gene, TF, 130-133 type-2 
transferrin receptor gene, TFR2,134,135 and the TMPRSS6 gene132,133,135 have 
been documented in humans and are associated with reduced iron status; thus 
genetics may also contribute to reduced iron status following RYGB. In the future, 
we would like to determine if SNPs are associated with measures of iron status in 
a cross-sectional study of RYGB patients. 
It is estimated that, since 1990, 1.4 million persons have undergone 
bariatric surgery in the United States alone.68 Therefore, it is imperative that we 
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